Glaukos iDose lifts US glaucoma sales 58%

Glaucoma treatment has a compliance problem. The standard therapy is usually a bottle of drops, used every day, for years. But lots of patients miss doses, stop early, or never use the drops quite right. Glaukos is betting that the cleaner fix is to move the drug into the eye itself — and this quarter suggests that bet is starting to work. In first-quarter 2026 results released April 29, the company said U.S. glaucoma sales rose 58% to $93.5 million, with iDose TR contributing about $54 million on its own. (investors.glaukos.com) ### What is iDose TR? iDose TR is a tiny intracameral implant — basically a small device placed inside the eye that slowly releases travoprost, a prostaglandin used to lower intraocular pressure in open-angle glaucoma or ocular hypertension. The FDA approved it in December 2023, and the label says it is indicated to reduce intraocular pressure in those patients. (accessdata.fda.gov) ### Why is that a big deal? Because the old model asks patients to behave like perfect machines. Glaucoma is chronic, often symptom-light at first, and easy to neglect. Drops can also sting, irritate the ocular surface, and create a lot of daily friction. An implant changes the workflow from “remember this every night” to “get a procedure, then let the drug do its job.” T(accessdata.fda.gov)thalmologists can deliver directly. (fool.com) ### Why does the revenue number matter so much? Because $54 million is not a side contribution. It is the engine. If U.S. glaucoma sales were $93.5 million and iDose TR was about $54 million, then the implant accounted for well over half of the segment in the quarter. That tells you adoption is not stuck in pilot mode. Surgeons are using it, payers are letti(fool.com)form story. It is already the glaucoma franchise. (investors.glaukos.com) ### What changed recently to help adoption? Re-administration is a big one. In January 2026, Glaukos said the FDA approved a supplemental NDA allowing iDose TR to be administered again. That matters because a one-time implant is useful, but a repeatable therapy is a real chronic-care product. The updated 2026 FDA label also reflects dosing and warning changes tied to that approval. (investors.glaukos.com) ### Is reimbursement part of the story? Yes — probably a huge part. New procedural therapies do not scale just because doctors like them. They scale when billing becomes legible and payment becomes predictable. Glaukos has been publishing reimbursement and coding guides for iDose and its interventional glaucoma products, which is the unglamorous plumbing behind commercial adoption. The catch is t(investors.glaukos.com) is never automatic. (glaukos.com) ### Does this mean eye drops are going away? No. Drops are cheap, familiar, and deeply embedded in care. But iDose is making the market look less binary than it used to. Instead of “drops first, surgery later,” Glaukos is pushing a middle lane — an office or OR-based drug-delivery procedure that behaves more like a device business than a pharmacy refill business. That is wh(glaukos.com)ed dosing to physician-delivered maintenance. (investors.glaukos.com) ### Bottom line The headline is not just that Glaukos grew fast. It is that iDose TR looks like a real category creator. When one implant can drive roughly $54 million in a quarter and lift U.S. glaucoma sales 58%, the story stops being theoretical. The market is starting to act like dropless glaucoma care is a business, not just an idea. (investors.glaukos.com)